Division of Respiratory Medicine, Dept of Pediatrics, Physiology and Experimental Medicine, Research Institute, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Pulmonary Function Testing and Clinical Trials Consultant, Rochester, MN, USA.
Eur Respir J. 2017 May 1;49(5). doi: 10.1183/13993003.01526-2016. Print 2017 May.
This international task force report updates general considerations for bronchial challenge testing and the performance of the methacholine challenge test. There are notable changes from prior recommendations in order to accommodate newer delivery devices. Rather than basing the test result upon a methacholine concentration (provocative concentration (PC) causing a 20% fall in forced expiratory volume in 1 s (FEV)), the new recommendations base the result upon the delivered dose of methacholine causing a 20% fall in FEV (provocative dose (PD)). This end-point allows comparable results from different devices or protocols, thus any suitable nebuliser or dosimeter may be used, so long as the delivery characteristics are known. Inhalation may be by tidal breathing using a breath-actuated or continuous nebuliser for 1 min (or more), or by a dosimeter with a suitable breath count. Tests requiring maximal inhalations to total lung capacity are not recommended because the bronchoprotective effect of a deep breath reduces the sensitivity of the test.
本国际工作组报告更新了支气管激发试验的一般注意事项和乙酰甲胆碱激发试验的操作。为了适应新型给药装置,与以往的推荐相比有显著的改变。新的推荐意见不是基于乙酰甲胆碱浓度(引起用力呼气量在 1 秒内下降 20%的激发浓度(PC))来确定试验结果,而是基于引起用力呼气量下降 20%的乙酰甲胆碱给药剂量(引起 20%用力呼气量下降的剂量(PD))来确定试验结果。这一终点可使不同设备或方案得出可比的结果,因此只要了解了给药特性,任何合适的雾化器或剂量计都可使用。可通过呼吸驱动或连续雾化器进行 1 分钟(或更长时间)的潮气呼吸吸入,或通过具有合适呼吸计数的剂量计吸入。不推荐使用需要最大吸气到肺总量的试验,因为深呼吸的支气管保护作用会降低试验的敏感性。